Emerald Mutual Fund Advisers Trust Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Emerald Mutual Fund Advisers Trust reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 13.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 295,317 shares of the biopharmaceutical company’s stock after selling 45,658 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.31% of Ultragenyx Pharmaceutical worth $10,738,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Motley Fool Wealth Management LLC raised its holdings in Ultragenyx Pharmaceutical by 83.9% in the 2nd quarter. Motley Fool Wealth Management LLC now owns 275,082 shares of the biopharmaceutical company’s stock valued at $10,002,000 after buying an additional 125,486 shares during the period. Motley Fool Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 98.2% during the second quarter. Motley Fool Asset Management LLC now owns 167,448 shares of the biopharmaceutical company’s stock worth $6,088,000 after purchasing an additional 82,975 shares during the period. Peregrine Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 11.8% during the second quarter. Peregrine Capital Management LLC now owns 189,520 shares of the biopharmaceutical company’s stock worth $6,891,000 after purchasing an additional 20,053 shares during the period. Teacher Retirement System of Texas increased its stake in Ultragenyx Pharmaceutical by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after purchasing an additional 404 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its stake in Ultragenyx Pharmaceutical by 110.3% during the second quarter. Y Intercept Hong Kong Ltd now owns 51,738 shares of the biopharmaceutical company’s stock worth $1,881,000 after purchasing an additional 27,138 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock opened at $34.59 on Thursday. The business has a 50-day simple moving average of $31.05 and a 200-day simple moving average of $32.96. The company has a market cap of $3.33 billion, a PE ratio of -6.25 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $53.47.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on RARE shares. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 price target on the stock. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $82.27.

Insider Buying and Selling

In related news, CFO Howard Horn sold 7,942 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,456 shares of company stock valued at $328,486 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.